JP7887366B2 - シヌクレイノパチーの処置のための組成物および方法 - Google Patents
シヌクレイノパチーの処置のための組成物および方法Info
- Publication number
- JP7887366B2 JP7887366B2 JP2022574541A JP2022574541A JP7887366B2 JP 7887366 B2 JP7887366 B2 JP 7887366B2 JP 2022574541 A JP2022574541 A JP 2022574541A JP 2022574541 A JP2022574541 A JP 2022574541A JP 7887366 B2 JP7887366 B2 JP 7887366B2
- Authority
- JP
- Japan
- Prior art keywords
- synuclein
- fusion protein
- cells
- domain
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026066932A JP2026120714A (ja) | 2020-06-05 | 2026-04-15 | シヌクレイノパチーの処置のための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063035297P | 2020-06-05 | 2020-06-05 | |
| US63/035,297 | 2020-06-05 | ||
| PCT/US2021/035958 WO2021248038A1 (en) | 2020-06-05 | 2021-06-04 | Compositions and methods for the treatment of synucleinopathies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026066932A Division JP2026120714A (ja) | 2020-06-05 | 2026-04-15 | シヌクレイノパチーの処置のための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023529371A JP2023529371A (ja) | 2023-07-10 |
| JP2023529371A5 JP2023529371A5 (cg-RX-API-DMAC7.html) | 2024-06-10 |
| JP7887366B2 true JP7887366B2 (ja) | 2026-07-09 |
Family
ID=76708439
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574541A Active JP7887366B2 (ja) | 2020-06-05 | 2021-06-04 | シヌクレイノパチーの処置のための組成物および方法 |
| JP2026066932A Pending JP2026120714A (ja) | 2020-06-05 | 2026-04-15 | シヌクレイノパチーの処置のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026066932A Pending JP2026120714A (ja) | 2020-06-05 | 2026-04-15 | シヌクレイノパチーの処置のための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230234997A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4161953A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7887366B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN116096737B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3183251A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021248038A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024026284A2 (en) * | 2022-07-25 | 2024-02-01 | Interius Biotherapeutics, Inc. | Mutated polypeptides, compositions comprising the same, and uses thereof |
| WO2024229777A1 (zh) * | 2023-05-11 | 2024-11-14 | 深圳先进技术研究院 | 一种aav载体及其应用 |
| CN116590342B (zh) * | 2023-05-11 | 2026-04-03 | 普递瑞(上海)医药有限公司 | 一种aav载体及其应用 |
| CN117402251B (zh) * | 2023-12-15 | 2024-02-23 | 中国医学科学院基础医学研究所 | 一种抗小g蛋白rbj的抗体及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004502781A (ja) | 2000-07-07 | 2004-01-29 | パナシア ファーマシューティカルズ インコーポレーテッド | 神経組織の損傷を予防するため、およびα−シヌクレイン疾患を処置するための方法 |
| JP2016500371A (ja) | 2012-12-05 | 2016-01-12 | ストラテジア・セラピューティクス・インコーポレイテッド | タンパク質発現増強ポリペプチド |
| WO2019161386A1 (en) | 2018-02-19 | 2019-08-22 | New York University | Alpha-synuclein single domain antibodies |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
| US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
| GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| EP1002119A1 (en) | 1997-07-31 | 2000-05-24 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Targeted hsv vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| DE69939169D1 (de) | 1998-05-28 | 2008-09-04 | Us Gov Health & Human Serv | Aav5 vektoren und deren verwendung |
| CN1246532A (zh) * | 1998-08-31 | 2000-03-08 | 复旦大学 | 人热休克关联蛋白编码序列、其编码的多肽及制备方法 |
| US7465583B2 (en) | 2000-06-01 | 2008-12-16 | The University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
| WO2002053703A2 (en) | 2001-01-05 | 2002-07-11 | Children's Hospital, Inc. | Aav2 vectors and methods |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| DK2359869T3 (en) | 2001-12-17 | 2019-04-15 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof |
| EP1668143B1 (en) | 2003-09-30 | 2013-03-20 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| EP1828390B1 (en) | 2004-12-15 | 2012-06-13 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
| WO2008002465A2 (en) * | 2006-06-23 | 2008-01-03 | The Feinstein Institute For Medical Research | INHIBITORS OF Aβ AND SYNUCLEIN AGGREGATION |
| EP2396343B1 (en) | 2009-02-11 | 2017-05-17 | The University of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| US9169494B2 (en) | 2010-01-12 | 2015-10-27 | The University Of North Carolina At Chapel Hill | Restrictive inverted terminal repeats for viral vectors |
| WO2011097456A2 (en) | 2010-02-05 | 2011-08-11 | The University Of North Carolina At Chapel Hill | Compositions and methods for enhanced parvovirus transduction |
| WO2014053879A1 (en) | 2012-10-04 | 2014-04-10 | Centre National De La Recherche Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| WO2018058088A1 (en) * | 2016-09-26 | 2018-03-29 | SOLA Biosciences, LLC | Cell-associated secretion-enhancing fusion proteins |
| WO2021138582A1 (en) * | 2019-12-31 | 2021-07-08 | The Johns Hopkins University | Fusion proteins and methods of use thereof |
-
2021
- 2021-06-04 US US18/007,978 patent/US20230234997A1/en active Pending
- 2021-06-04 CN CN202180058141.7A patent/CN116096737B/zh active Active
- 2021-06-04 WO PCT/US2021/035958 patent/WO2021248038A1/en not_active Ceased
- 2021-06-04 JP JP2022574541A patent/JP7887366B2/ja active Active
- 2021-06-04 CA CA3183251A patent/CA3183251A1/en active Pending
- 2021-06-04 EP EP21736438.9A patent/EP4161953A1/en active Pending
-
2026
- 2026-04-15 JP JP2026066932A patent/JP2026120714A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004502781A (ja) | 2000-07-07 | 2004-01-29 | パナシア ファーマシューティカルズ インコーポレーテッド | 神経組織の損傷を予防するため、およびα−シヌクレイン疾患を処置するための方法 |
| JP2016500371A (ja) | 2012-12-05 | 2016-01-12 | ストラテジア・セラピューティクス・インコーポレイテッド | タンパク質発現増強ポリペプチド |
| WO2019161386A1 (en) | 2018-02-19 | 2019-08-22 | New York University | Alpha-synuclein single domain antibodies |
Non-Patent Citations (2)
| Title |
|---|
| SCIENTIFIC REPORTS,2017年,Vol.7, No.1,p.1-13 |
| THE JOURNAL OF BIOLOGICAL CHEMISTRY,2015年,Vol.290, No.12,p.7426-7435 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230234997A1 (en) | 2023-07-27 |
| CN116096737B (zh) | 2026-06-26 |
| JP2026120714A (ja) | 2026-07-22 |
| JP2023529371A (ja) | 2023-07-10 |
| WO2021248038A1 (en) | 2021-12-09 |
| CA3183251A1 (en) | 2021-12-09 |
| CN116096737A (zh) | 2023-05-09 |
| EP4161953A1 (en) | 2023-04-12 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240531 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240531 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250520 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250808 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251117 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20251216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260415 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260604 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260629 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7887366 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |